Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / VERU
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Veru Inc. VERU

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$-22.7M
$-30.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

On December 30, 2024, the Company sold its FDA-approved commercial product, the FC2 Female Condom® (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections (the “FC2 Business”). Veru is a Wisconsin corporation that is the successor to The Wisconsin Pharmacal Company, Inc. On July 31, 2017, we changed our corporate name from “The Female Health Company” to “Veru Inc.” reflecting our focus on developing and commercializing biopharmaceutical products. As of December 1, 2025, the Company had 20 full-time employees, all of whom are located in the U.S.

Written from the business description in Veru Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 17 December 2025. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2024 · Revenue 16.9 · Net income -37.8
25.0M50.0M-40.0M-80.0M
2009201220152018202120242025
Compound annual growth
−34.9%
−11.9%
−3.6%
−3.2%
+1.6%
−90.1%
−72.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −11.9% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -214.2% · Net -223.9%
-200%-400%
200920172025
ROE
FY2025 · ROE -89.7%
20%40%60%-50%-100%-150%
200920172025
Three returns, three denominators.
Gross margin·
Operating margin·
Net margin·
EBITDAUSD -24.6M

Each USD of equity lost 90 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -30.0
5M10M-40M-80M
200920172025
Net buybacks $M Dividends $M
FY2015 · Dividends 0.0 · Net buybacks 0.0
3M6MDividendsNet buybacks
2009201020112012201320142015
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises1 year

Total assetsUSD 29.8M
EquityUSD 18.3M
CashUSD 15.8M
Current ratio2.43×

Equity funds 61% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
VERU, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B◌0.00.00.00.10.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.1−0.10.0−0.0−0.0−0.0−0.00.00.00.00.00.00.00.00.0
EBITDA $B−0.0−0.0−0.1−0.10.0−0.0◌−0.0−0.00.00.00.00.00.00.00.00.0
Income tax $B0.00.00.00.0−0.0−0.0−0.00.0−0.00.00.00.0−0.0−0.0−0.0−0.0−0.0
Net income $B−0.0−0.0−0.1−0.10.0−0.0−0.0−0.0−0.00.00.00.00.00.00.00.00.0
Free cash flow $B−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.00.0−0.0−0.00.00.00.00.00.00.0
EPS, diluted $◌◌−1.10−1.050.09−0.28−0.19−0.44−0.250.010.150.080.500.530.190.240.24
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌0.210.070.220.20◌◌
Payout %——————————0250524010361—
ROE %−89.7−145.4−181.8−70.88.0−60.8−38.9−61.4−16.11.014.28.251.674.732.846.350.4
Shares out B0.010.150.090.080.080.070.070.060.050.030.030.030.030.030.030.03◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 82 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inWisconsin
Fiscal year endsSeptember 30
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image